Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Efgartigimod PH20 SC Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report delivers a comprehensive assessment of the commercial outlook for efgartigimod PH20 SC, marketed as VYVGART HYTRULO, across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers historical performance, current market dynamics, and sales forecasts from 2020 through 2034.
The report evaluates efgartigimod PH20 SC in approved indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), alongside potential indications such as bullous pemphigoid, Graves' ophthalmopathy, myositis, pemphigus, Sjogren's syndrome, lupus nephritis, and renal transplant rejection. It also examines regulatory milestones, clinical development, pricing, reimbursement, competitive positioning, patent considerations, and potential generic entry.
Key Factors Driving Efgartigimod PH20 SC Market Growth
- Strong commercial momentum: The VYVGART franchise has recorded rapid global growth. argenx reported net product sales of approximately US$790 million in the first quarter of 2025 and US$949 million in the second quarter, representing 97% operational year-over-year growth in Q2 2025. Increasing adoption of the subcutaneous formulation in gMG and CIDP has contributed significantly to this performance.
- Expanded self-administration options: In April 2025, the US Food and Drug Administration approved a prefilled syringe version of VYVGART HYTRULO for self-injection by eligible patients with gMG or CIDP. Administration in approximately 20-30 seconds may reduce reliance on infusion centers, improve treatment accessibility, and support broader use in community and home settings.
- Multi-indication development: argenx is evaluating its pipeline across approximately 15 autoimmune diseases. Programs involving immune thrombocytopenia, ocular myasthenia gravis, pemphigus, inflammatory myopathies, and other immune-mediated disorders could extend the product's commercial lifecycle and diversify future revenue.
- Clinical validation of FcRn inhibition: Efgartigimod was the first approved neonatal Fc receptor inhibitor. Growing clinical experience with the FcRn therapeutic class, favorable adoption in neuromuscular disorders, and continued investment by competing developers support the long-term market opportunity.
- International market expansion: VYVGART HYTRULO has advanced across markets in Europe, Japan, and China. New reimbursement pathways, regulatory progress, deeper market penetration, and longer treatment duration may support continued international sales growth.
Recent Efgartigimod PH20 SC Developments
In April 2026, argenx presented new VYVGART data in myasthenia gravis and CIDP at the American Academy of Neurology Annual Meeting in Chicago. The presentations included findings for intravenous VYVGART and subcutaneous VYVGART HYTRULO, as well as updates on adimanebart in congenital myasthenic syndromes and the company's broader neuromuscular pipeline. This pipeline includes Phase III studies evaluating empasiprubart in CIDP.
Efgartigimod PH20 SC Product Overview
VYVGART HYTRULO combines efgartigimod alfa with recombinant human hyaluronidase PH20 and is administered subcutaneously. Developed by argenx using hyaluronidase technology licensed from Halozyme Therapeutics, the therapy targets FcRn and reduces circulating immunoglobulin G, including pathogenic IgG autoantibodies.
Clinical studies in gMG and CIDP have reported reductions in IgG levels and improvements in relevant measures of muscle strength, disability, and quality of life, with a generally favorable safety profile. Reported adverse events include injection-site reactions, headache, respiratory tract infections, and urinary tract infections. The therapy received FDA approval for anti-acetylcholine receptor antibody-positive gMG in 2023 and for CIDP in 2024, becoming the first FcRn inhibitor approved for CIDP.
Scope of the Efgartigimod PH20 SC Market Report
- Current and forecasted efgartigimod PH20 SC sales through 2034 across the 7MM.
- Market size analysis for approved and potential autoimmune indications.
- Product assessment covering mechanism of action, dosage, administration, safety, and efficacy.
- Clinical trial analysis, including interventions, study status, timelines, and anticipated completion dates.
- Regulatory milestones, expected launches, designations, and regional development activities.
- Pricing, treatment cost estimates, reimbursement conditions, and geographic cost variations.
- Patent landscape, generic-entry considerations, and the potential effect of competition on pricing.
- SWOT analysis, analyst perspectives, market barriers, growth drivers, and commercial opportunities.
- Competitive intelligence covering marketed products, late-stage pipeline therapies, expected launch dates, partnerships, licensing transactions, and merger and acquisition activity.
Market and Competitive Analysis
The efgartigimod PH20 SC market forecast assesses projected revenue, peak sales potential, prescription growth, treatment duration, and uptake across approved and anticipated indications. It also evaluates the product's market positioning against established therapies and emerging competitors, including its clinical differentiation, administration profile, strengths, weaknesses, and potential commercial risks.
The competitive landscape is expected to evolve as additional FcRn inhibitors and other targeted autoimmune therapies reach the market. Late-stage products in gMG, CIDP, and potential expansion indications may influence pricing, reimbursement, market share, and treatment sequencing. However, VYVGART HYTRULO's early market entry, established clinical profile, expanding international presence, and self-administration option may support continued uptake.
Report Methodology
The analysis is based on internal databases, primary research, secondary research, and in-house review by industry experts. Sources include regulatory authorities, clinical trial registries, company disclosures, medical and trade journals, industry associations, white papers, news publications, and subscription databases. Findings are consolidated to provide an evidence-based view of the efgartigimod PH20 SC market, sales outlook, and competitive environment.
Key Report Highlights
- Demand for efgartigimod PH20 SC is expected to benefit from rising prescriptions, broader patient access, and expansion into additional immune-mediated diseases.
- Self-administration may improve convenience and reduce dependence on facility-based treatment.
- Regulatory and reimbursement progress across major international markets may expand the addressable patient population.
- Pipeline competition could affect future market share, pricing, and treatment positioning.
- Sales forecasts through 2034 provide strategic insights for portfolio planning, commercialization, investment evaluation, and market-entry decisions.
The report addresses critical strategic questions concerning efgartigimod PH20 SC's clinical and commercial performance, forecast assumptions, regional sales potential, treatment costs, regulatory designations, competitive threats, development timelines, and opportunities across approved and potential indications. It is designed to support pharmaceutical companies, investors, healthcare consultants, market-access teams, and other stakeholders evaluating the future of VYVGART HYTRULO and the expanding FcRn inhibitor market.
For more information about this report visit https://www.researchandmarkets.com/r/gphi2x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
